source
- Enveda reports promising Phase 1 data for oral drug that mimics exercise to preserve muscle during weight lossEnveda, a biotech based in Boulder, Colorado, announced Phase 1 results for its oral candidate ENV-308, a chemically engineered version of the metabolite lactate phenylalanine (lac-phe). The metabo…
- STAT+: Amylyx endocrine drug succeeds in pivotal studyIn a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with…STAT · 1h ago↗ source